FY2025 Earnings Estimate for Humana Issued By Zacks Research

Key Points

• Analysts at Zacks Research have raised their FY2025 earnings estimate for Humana to $16.99 per share, up from $16.25, indicating a positive outlook for the insurance provider.
• Humana's recent quarterly earnings report showed a 6.27 EPS, missing expectations, yet it achieved a revenue of $32.39 billion, exceeding the consensus estimate by approximately $540 million.
• Despite some downgrades from various research firms, Humana holds a consensus rating of "Hold" with a target price of $281.45 among analysts.

Humana Inc. (NYSE:HUM - Free Report) - Analysts at Zacks Research raised their FY2025 earnings estimates for Humana in a research report issued on Wednesday, August 13th. Zacks Research analyst D. Chatterjee now expects that the insurance provider will post earnings per share of $16.99 for the year, up from their prior forecast of $16.25. The consensus estimate for Humana's current full-year earnings is $16.47 per share. Zacks Research also issued estimates for Humana's Q2 2027 earnings at $6.95 EPS.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. During the same period in the prior year, the business earned $6.96 EPS. The company's revenue for the quarter was up 9.6% compared to the same quarter last year.

A number of other research firms also recently weighed in on HUM. Wall Street Zen downgraded shares of Humana from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Wells Fargo & Company decreased their price target on shares of Humana from $348.00 to $344.00 and set an "overweight" rating on the stock in a research note on Thursday. Morgan Stanley decreased their price target on shares of Humana from $290.00 to $277.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 31st. Bank of America decreased their price target on shares of Humana from $320.00 to $260.00 and set a "neutral" rating on the stock in a research note on Tuesday, June 17th. Finally, Raymond James Financial upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price target on the stock in a research note on Thursday, May 1st. Eighteen research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $281.45.

Humana Stock Performance

Shares of Humana stock traded up $6.77 during midday trading on Friday, hitting $288.11. The company had a trading volume of 369,648 shares, compared to its average volume of 1,727,203. The business's 50 day simple moving average is $241.58 and its two-hundred day simple moving average is $253.94. The stock has a market cap of $34.65 billion, a PE ratio of 22.11, a P/E/G ratio of 1.66 and a beta of 0.44. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. Humana has a 1-year low of $206.87 and a 1-year high of $382.72.

Institutional Trading of Humana

A number of hedge funds have recently modified their holdings of the company. Cary Street Partners Investment Advisory LLC raised its position in shares of Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock valued at $31,000 after acquiring an additional 46 shares during the period. Riverview Trust Co acquired a new stake in shares of Humana in the 1st quarter valued at approximately $34,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of Humana in the 2nd quarter valued at approximately $32,000. Garde Capital Inc. acquired a new stake in shares of Humana in the 1st quarter valued at approximately $36,000. Finally, Zions Bancorporation National Association UT acquired a new stake in shares of Humana in the 1st quarter valued at approximately $37,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.